Global Anthelmintic Drugs Market Size By Type (Oral Drugs, Injectables), By Application (For Human, For Animal), By Region, And Segment Forecasts, 2023 to 2032

The Global Anthelmintic Drugs Market was valued at USD 3.2 billion in 2023 and is projected to reach USD 5.6 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2023–2031). The rising prevalence of helminthic infections in both humans and animals, increasing awareness regarding parasitic diseases, and government initiatives for mass deworming programs are the primary drivers fueling the market. Anthelmintic drugs play a vital role in veterinary and human healthcare by treating infections caused by parasitic worms, including roundworms, tapeworms, and flukes.

Drivers:

1. Increasing Prevalence of Helminthic Infections

Globally, millions are affected by soil-transmitted helminths, especially in tropical and subtropical regions with poor sanitation. The increasing need to manage these infections is boosting demand for effective anthelmintics.

2. Veterinary Health Emphasis

The rising global demand for meat and dairy, along with heightened concern for animal health, is driving the use of dewormers in livestock and pets. Companion animal care also contributes significantly to the market.

3. Government and NGO-led Deworming Initiatives

Programs such as the WHO's global deworming efforts and national campaigns (e.g., India's National Deworming Day) are key to boosting market penetration, especially in developing regions.

Restraints:

1. Drug Resistance

Overuse and misuse of certain anthelmintics have led to resistance in parasite populations, particularly in livestock. This trend is challenging market sustainability and efficacy standards.

2. Limited R&D for Novel Molecules

Despite the public health burden, the development of new drug classes remains slow due to low ROI, regulatory hurdles, and high R&D costs.

Opportunity:

1. Advancements in Drug Formulation and Delivery

Innovations such as extended-release formulations and combination therapies present opportunities to improve compliance and treatment efficacy.

2. Expansion in Emerging Economies

Rising healthcare infrastructure and livestock production in countries like India, Brazil, and Southeast Asia offer lucrative market potential for both human and veterinary applications.

Market by System Type Insights:

Based on drug class, the Benzimidazole segment dominated the market in 2023, owing to its broad-spectrum efficacy and cost-effectiveness. Albendazole and Mebendazole are widely used across various applications. However, the Macrocyclic Lactones segment (e.g., ivermectin) is poised for strong growth due to its increasing adoption in mass drug administration (MDA) programs.

Market by End-use Insights:

In terms of end-use, Veterinary Use accounted for the largest revenue share in 2023, with widespread adoption in livestock deworming. The Human Health segment is also growing rapidly due to expanded access to anthelmintic therapy via global health programs.

Market by Regional Insights:

Asia-Pacific emerged as the leading region in 2023 due to high disease burden, ongoing deworming campaigns, and growth in animal husbandry. Latin America and Africa are also witnessing strong adoption due to neglected tropical disease (NTD) interventions. Meanwhile, North America and Europe focus more on veterinary anthelmintics for companion animals and livestock.

Competitive Scenario:

Key players in the market include Pfizer Inc., Bayer AG, Boehringer Ingelheim, Zoetis Inc., Merck & Co., Elanco Animal Health, Virbac, Novartis AG, Vetoquinol, and Sanofi S.A. These companies focus on strategic acquisitions, global expansion, and R&D investments to innovate novel formulations and maintain regulatory compliance.

Scope of Work – Global Anthelmintic Drugs Market

Key Market Developments:

2023: Merck launched a next-gen veterinary dewormer targeting resistant strains in livestock, enhancing spectrum coverage and reducing dosing frequency.

2024: Zoetis acquired a regional veterinary pharmaceutical firm to strengthen its presence in Asia-Pacific markets.

2025: Bayer introduced a pediatric-friendly chewable albendazole formulation, supporting compliance in public health deworming campaigns.

FAQs:

1) What is the current market size of the Global Anthelmintic Drugs Market?

The market was valued at USD 3.2 billion in 2023.

2) What is the major growth driver of the Global Anthelmintic Drugs Market?

The major growth driver is the rising prevalence of parasitic infections in humans and animals globally.

3) Which is the largest region during the forecast period in the Global Anthelmintic Drugs Market?

Asia-Pacific is expected to remain the largest region due to high disease burden and expanding livestock farming.

4) Which segment accounted for the largest market share in the Global Anthelmintic Drugs Market?

The Veterinary Use segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Anthelmintic Drugs Market?

Key players include Pfizer Inc., Bayer AG, Boehringer Ingelheim, Zoetis Inc., Merck & Co., Elanco, and Virbac.